Cellumed Co.,Ltd. (KOSDAQ:049180)

Market Cap	58.56B
Revenue (ttm)	119.64B
Net Income (ttm)	-30.92B
Shares Out	51.51M
EPS (ttm)	-661.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	610,820
Average Volume	1,243,765
Open	1,207.00
Previous Close	1,188.00
Day's Range	1,132.00 - 1,207.00
52-Week Range	1,008.00 - 4,415.00
Beta	0.94
RSI	25.31
Earnings Date	Mar 21, 2025

About Cellumed

Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. The company offers CLnZyme, a mRNA enzyme; cosmeceuticals, such as FGF7 for skin regeneration and TGFβ-1 for tissue regeneration; and electric motorcycles. It provides tissue bank products, such as celluderm powder, ultra, and HD implant for the skin; patellar tendon hemi whole, posterior tibialis, anterior tibialis, semitendinosus, gracilis, and peroneus longus tendons, and meniscus lateral and medial; cancellous bone ...

• Industry: Business Services, not elsewhere classified
• Founded: 1985
• Employees: 89
• Stock Exchange: KOSDAQ
• Ticker Symbol: 049180

Financial Performance

In 2023, Cellumed's revenue was 95.55 billion, a decrease of -21.73% compared to the previous year's 122.09 billion. Losses were -37.30 billion, 569.5% more than in 2022.